60 results about "Hepatitis virus" patented technology

The present disclosure encompasses a lipid nanoparticle (LNP) comprising a polypeptide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a recognition sequence within a Hepatitis B virus (HBV) genome. Further, the disclosure encompasses pharmaceutical compositions comprising the LNPs, and the use of such compositions for inactivating a pol gene of an HBV genome or an HBV genome fragment in a cell and treating HBV infections or diseases associated with HBV infections.

The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).

This disclosure provides a recombinant hepatitis C virus glycoprotein comprising heterodimers of E1 and E2 glycoproteins having at least 60% homology with SEQ ID No. 1, engineered furin protease cleavage sites, and hydrophilic amino acid linkers, wherein the E1 and E2 glycoproteins partially or completely lack their respective transmembrane domains. This document further provides nucleic acids encoding the recombinant hepatitis C virus glycoprotein, nanoparticle conjugates comprising the recombinant hepatitis C virus glycoprotein, and compositions comprising the recombinant hepatitis C virus glycoprotein, the nucleic acid, or the nanoparticle conjugate. Applications of the recombinant hepatitis C virus glycoprotein or compositions comprising the glycoprotein are also envisioned.

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The present invention relates to a hepatitis delta virus (HDV) polypeptide comprising an antigenic domain comprising an amino acid sequence of SEQ ID NO:1 or an amino acid sequence at least 60% identical thereto, wherein said polypeptide (i) is devoid of a coiled-coil domain consisting of the amino acid sequence of SEQ ID NO:2 or an amino acid sequence at least 60% identical thereto; or (ii) further comprises said coiled-coil domain, wherein said coiled-coil domain comprises at least one of the following mutations: (I) the amino acid at position 20 is not tryptophan, and (II) the amino acid at position 50 is not tryptophan. Moreover, the present invention relates to proteins, kits, polynucleotides, host cells, methods, and devices related thereto.

The invention discloses a construction method and application of a hepatitis D virus replication mouse model. Experiments prove that the generation of HDV RNA and the expression of HDAg protein in mouse liver tissues can be maintained by performing caudal vein high-pressure injection on the pSVL (D3) plasmid. The invention provides a novel mouse model for HDV research, provides a new in-vivo platform for anti-HDV drug screening and vaccine evaluation, and has wide application prospects and market potential.

An object of the present invention is to provide a pharmaceutical composition useful as a novel anti-hepatitis B virus agent and a screening method. According to the present invention, there is provided a pharmaceutical composition that inhibits the production of a hepatitis B virus protein, in which the pharmaceutical composition inhibits the expression or the function of a protein belonging to the YTHDC family.

Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses, Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.

The present disclosure provides methods for treating HBV infection using combination therapies in patients with serum HBsAg levels below 3000 IU / mL prior to treatment. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).

A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

The invention provides siRNA for targeted degradation of hepatitis B viruses HBsAg and HBX mRNA, and relates to the technical field of biological medicines. A positive-sense strand of the siRNA comprises a base sequence as shown in SEQ ID NO. 1, and an antisense strand of the siRNA comprises a base sequence as shown in SEQ ID NO. 2; or, the positive-sense strand comprises the base sequence as shown in SEQ ID NO. 3, and the antisense strand comprises the base sequence as shown in SEQ ID NO. 4. The siRNA and the siRNA conjugate provided by the invention can significantly inhibit expression of HBsAg and HBX by targeting HBV, which indicates that the siRNA and the siRNA conjugate can be used as effective components for preparing anti-HBV drugs and for treating hepatitis B caused by HBV.

The present disclosure provides methods for treating HBV infection using an siRNA that targets an HBV gene. In some embodiments, the method for treating HBV involves co-administration of siRNA with PEG-INFα.

The present application belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition with the effect of preventing and / or treating hepatitis B. The traditional Chinese medicine composition is mainly prepared from Notopterygium incisum, Angelica pubescens, Poria cocos, Saposhnikovia divaricata, Schizonepeta tenuifolia, Chuanxiong, Platycodon grandiflorum, Bupleurum chinense, Peucedanum praeruptorum, Citrus aurantium, and Glycyrrhiza uralensis. The traditional Chinese medicine composition can not only significantly inhibit the activity of hepatitis B virus, but also significantly inhibit the secretion of HBSAg and HBeAg of hepatitis B virus, inhibit rebound after drug withdrawal, has a significant preventive and / or therapeutic effect on liver damage caused by hepatitis B virus infection, and can promote the production of hepatitis B surface antibody, thus having a broad clinical application prospect.

The invention relates to a crystal form of an antiviral prodrug nucleoside cyclic phosphate compound for liver delivery as well as a preparation method and application of the crystal form, in particular to a polymorphic form of (2R)-9-{2-[(2R, 4S)-4-(5-chloro-2-fluorophenyl)-2-oxo-1, 3, 2-dioxaphosphohexane-2-yl] methoxy propyl} adenine as shown in a formula (I) and a salt thereof as well as a preparation method and application of the polymorphic form of the (2R)-9-{2-[(2R, 4S)-4-(5-chloro-2-fluorophenyl)-2-oxo-1, 3, 2-dioxaphosphohexane-2-yl] methoxy propyl} adenine. The crystal form disclosed by the invention has the characteristics of high bioavailability, remarkable drug effect, good stability, high yield, high purity and the like, and can be used for independently treating hepatitis B virus (HBV), hepatitis D virus (HDV), human immunodeficiency virus (HIV) and diseases caused by the hepatitis B virus (HBV), the hepatitis D virus (HDV) and the human immunodeficiency virus (HIV) or the hepatitis D virus (HDV) and the human immunodeficiency virus (HIV) together with other antiviral drugs.

The application discloses a recombinant virus-like nanoparticle for immunotherapy of gastric cancer and application thereof. The recombinant virus-like nanoparticle is a chimeric recombinant virus-like nanoparticle formed by self-assembly of a fusion protein HBC-CLDN18.2 of a hepatitis B virus core protein and CLDN18.2 tight junction protein. The application uses genetic engineering technology to truncate the C-terminal end of a natural hepatitis B virus core antigen, and mutate cysteine residues at positions 48 and 107 into serine, so that the hepatitis B virus core antigen can self-assemble into a virus-like nanoparticle with strong stability. The virus-like nanoparticle is used as a carrier, a B cell epitope peptide (tight junction protein CLDN18.2) of a gastric cancer tumor-related antigen is inserted into an immunodominant site of the carrier, so that the humoral immune response against gastric cancer is enhanced. Two T cell epitope peptides of the heterologous hepatitis B virus core antigen are used to replace T cell epitope peptides on the carrier, so that the cellular immune response against gastric cancer is enhanced, and strong antitumor effect and immune memory effect are shown.

Disclosed herein are identified compound fragments, compounds and their pharmaceutically acceptable salts, isotopes or solvates, useful as antiviral drug and / or as a hepatic-targeted drug, such as for the treatment of HBV, HDV and / or HIV.

The invention provides an antibody for resisting an asialoglycoprotein receptor as well as a preparation method and application of the antibody. The antibody for resisting the asialoglycoprotein receptor comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain variable region HCDR1-HCDR3; and the light chain variable region comprises a light chain variable region LCDR1-LCDR3. According to the present invention, the affinity of the anti-asialoglycoprotein receptor antibody to the human asialoglycoprotein receptor is 0.425 nM, and the antigen recognition ability is strong; the compound disclosed by the invention can be used for remarkably inhibiting the DNA expression of HBsAg, HBeAg and HBV of HepG2.2. 15 cells and HepAD38 cells, has a function of inhibiting the replication of the hepatitis B virus, and has a great application prospect in medicines for preventing and / or treating hepatitis B virus infection and / or preventing and / or treating related diseases caused by the hepatitis B virus infection.

The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising at least parts of the HCV core protein, and HCV E1 and HCV E2 protein of a specific HCV strain, as well as VSV-G protein. The proteins may be assembled in rVSV-HCV particles. This has been identified to induce particularly advantageous broadly neutralizing antibodies. The invention further provides nucleic acids encoding said HCV proteins and VSV proteins but not encoding VSV-G protein. Vaccines comprising the particles, compositions or nucleic acids are disclosed as useful, in particular, for prophylactic vaccination against HCV. Methods of producing the rVSV-HCV particles or compositions of the invention and the produced particles and compositions are also subject-matter of the invention.

The present disclosure provides methods for treating hepatitis D virus (HDV) infection and / or an HDV-associated disease using combination therapies, and related kits and compositions for use in such methods. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).

The invention relates to a sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor and application thereof, and provides a sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor and application of the sodion-taurocholic acid co-transport protein (NTCP) long-acting inhibitor. In particular, provided are long-acting polypeptides that can be used as NTCP inhibitors. The invention also relates to a preparation method and application of the polypeptide, and a pharmaceutical composition containing the polypeptide. The NTCP long-acting inhibitor competitively inhibits the binding between hepatitis virus surface protein and NTCP through binding with NTCP, realizes the hepatitis virus entry inhibition effect, and can be used as a therapeutic or prophylactic drug for blocking hepatitis virus from entering cells, a hepatitis recurrence inhibition drug and a hepatitis functional curing drug; the compound can also be used as a medicine for treating type II diabetes, a medicine for treating obesity and a medicine for treating intestinal autoimmune diseases, biliary cirrhosis and atherosclerosis.

The present invention relates to a crystal form of a liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound, a preparation method therefor, and a use thereof, and in particular to a polymorph of (2R)-9-{2-[(2R, 4S)-4-(5-chloro-2-fluorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]methoxypropyl}adenine and a salt thereof, a preparation method for the polymorph and a use of the polymorph. The crystal form of the present invention has the characteristics of high bioavailability, significant efficacy, good stability, high yield, high purity and the like, and can be used alone or in combination with other antiviral drugs to treat hepatitis B virus (HBV), hepatitis D virus (HDV), human immunodeficiency viruses (HIV), and diseases caused thereby.

Virus-Like Particles derived from the subfamilies, Parahepevirinae, which infect trout and salmon, and the Orthohepevirinae, which infect mammals and birds, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are also disclosed. Major aspects of the invention relate to compositions of Virus-Like Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus-Like Particles. Preferred aspects relate to functional capsids comprising polypeptide sequences comprising one or more amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, wherein said variant polypeptides are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV). Other aspects include the design and assembly of modified vectors to facilitate the basic and applied studies leading to the development and commercialization of novel drug products, and as tools advancing the interests of institutions involved in animal and human healthcare.

There is provided a method of curing chronic hepatitis B infection in a human, the method comprising administering to a subject in need thereof an effective amount of one or both of an exogenous anti-HBs antibody or an anti-HBs antibody producing carrier, the present invention relates to a method for reducing cellular and blood hepatitis B surface antigen (HBsAg) by providing continuously increased levels of anti-HBs antibodies in the subject.

The present invention relates to a hepatitis A virus production method and hepatitis A virus produced according to the method, and, more specifically, to: a hepatitis A virus production method and hepatitis A virus produced according to the method, the method comprising the step of infecting a host cell with a virus obtained by transforming a host cell with a vector comprising an expression cassette, which comprises a hepatitis A virus gene, for hepatitis A virus preparation, and subculturing same.

Provided herein are methods for treating chronic hepatitis B (CHB) infections in human subjects. In some embodiments, the methods involve administering a lipid nanoparticle carrying an epigenetic-modifying DNA targeting system composed of polynucleotides for targeting repression of total Hepatitis B Viral (HBV) transcripts. Also provided is a lipid nanoparticle carrying the polynucleotides.

The invention provides a genetic expression cassette comprising, in order from 5'-3':an 5' adenoassociated viral (AAV) inverted terminal repeat (ITR), the elongation factor 1 long promoter, a chimeric intron, a 5' UT translational enhancer element containing a Kozak sequence, a polynucleotide comprising a nucleic acid sequence with at least 80% identity to the nucleic acid sequence of either wild-type of propionyl-CoA carboxylase beta (PCCB or synPCCB1), the hepatitis B virus derived post-translational response element, the bovine growth hormone poly-adenylation sequence, and an 3' AAV inverted ITR. The invention also provides expression vectors comprising the inventive cassette, compositions comprising the same, and methods for treating a disease or condition mediated by propionyl-CoA carboxylase.

Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and / or treating hepatitis B virus (HBV) and / or hepatitis D virus (HDV) infections in an animal or diseases related to said infections, wherein the substance prevents or reduces the interaction between HBV and / or HDV and an organic anion transporting polypeptide (OATP) in the animal, and / or prevents or reduces the expression and / or function of OATP in the animal. Further provided in the present invention are a cell model and an animal model having susceptibility to HBV and / or HDV that are obtained by means of transferring an exogenous SLCO gene into a cell or expressing an exogenous OATP protein, and a method for establishing the models; a method for delivering a drug by means of targeting OATP, and a drug delivery vehicle targeting OATP; and an OATP-targeted delivery polypeptide vehicle derived from a hepadnaviridae surface antigen.